• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Treatment of myocardial fibrosis in systemic sclerosis with tocilizumab.

作者信息

Ishizaki Yoshiki, Ooka Seido, Doi Shunichi, Kawasaki Tatsuya, Sakurai Keiichi, Mizushima Machiko, Kiyokawa Tomofumi, Takakuwa Yukiko, Tonooka Kumiko, Kawahata Kimito

机构信息

Division of Rheumatology and Allergology, Shunichi Doi Division of Cardiology, Department of Internal Medicine, St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.

出版信息

Rheumatology (Oxford). 2021 Jun 18;60(6):e205-e206. doi: 10.1093/rheumatology/keaa865.

DOI:10.1093/rheumatology/keaa865
PMID:33331892
Abstract
摘要

相似文献

1
Treatment of myocardial fibrosis in systemic sclerosis with tocilizumab.用托珠单抗治疗系统性硬化症中的心肌纤维化。
Rheumatology (Oxford). 2021 Jun 18;60(6):e205-e206. doi: 10.1093/rheumatology/keaa865.
2
COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD.一名接受托珠单抗治疗系统性硬化症相关间质性肺病的系统性硬化症患者感染了新冠病毒。
Ann Rheum Dis. 2020 May;79(5):668-669. doi: 10.1136/annrheumdis-2020-217442. Epub 2020 Apr 2.
3
New developments in juvenile systemic and localized scleroderma.青少年系统性和局限性硬皮病的新进展。
Rheum Dis Clin North Am. 2013 Nov;39(4):905-20. doi: 10.1016/j.rdc.2013.05.003. Epub 2013 Jul 16.
4
Treatment of systemic sclerosis with tocilizumab.用托珠单抗治疗系统性硬化症。
Rheumatology (Oxford). 2015 Feb;54(2):371-2. doi: 10.1093/rheumatology/keu435. Epub 2014 Dec 5.
5
Tocilizumab for systemic sclerosis with cardiac involvement: a case report.托珠单抗治疗合并心脏受累的系统性硬化症：一例报告
Clin Exp Rheumatol. 2022 Oct;40(10):2006-2007. doi: 10.55563/clinexprheumatol/cibdmf. Epub 2022 Sep 30.
6
Tocilizumab for systemic sclerosis: implications for future trials.托珠单抗治疗系统性硬化症：对未来试验的启示
Lancet. 2016 Jun 25;387(10038):2580-2581. doi: 10.1016/S0140-6736(16)00622-X. Epub 2016 May 5.
7
Systemic sclerosis-associated interstitial lung disease treated with tocilizumab.用托珠单抗治疗的系统性硬化症相关间质性肺病
Intern Med J. 2021 Jun;51(6):999-1000. doi: 10.1111/imj.15359.
8
Critical finger ischemia and myocardial fibrosis development after sudden interruption of sildenafil treatment in a systemic sclerosis patient.一名系统性硬化症患者突然中断西地那非治疗后出现严重手指缺血和心肌纤维化。
Reumatismo. 2016 Sep 9;68(2):109-11. doi: 10.4081/reumatismo.2016.889.
9
A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis?1例托珠单抗成功治疗重叠综合征：难治性皮肌炎的一种有希望的治疗策略？
Rheumatology (Oxford). 2014 Oct;53(10):1907-8. doi: 10.1093/rheumatology/keu234. Epub 2014 May 23.
10
Tocilizumab reduced production of systemic sclerosis-related autoantibodies and anti-cyclic citrullinated protein antibodies in two patients with overlapping systemic sclerosis and rheumatoid arthritis.托珠单抗降低了两名重叠性系统性硬化症和类风湿关节炎患者体内系统性硬化症相关自身抗体及抗环瓜氨酸化蛋白抗体的产生。
Scand J Rheumatol. 2018 May;47(3):248-250. doi: 10.1080/03009742.2017.1297482. Epub 2017 May 8.

引用本文的文献

1
Tocilizumab combined with cyclophosphamide for the treatment of rapidly progressive refractory systemic sclerosis with predominant cardiac involvement: a case report.托珠单抗联合环磷酰胺治疗以心脏受累为主的快速进展性难治性系统性硬化症：一例报告
Front Immunol. 2025 Jul 3;16:1614714. doi: 10.3389/fimmu.2025.1614714. eCollection 2025.
2
Anti-SRP Antibodies and Myocarditis in Systemic Sclerosis Overlap Syndrome with Immune-Mediated Necrotizing Myositis (IMNM).抗 SRP 抗体与免疫介导性坏死性肌炎重叠的系统性硬化症中的心肌炎 (IMNM)。
Medicina (Kaunas). 2024 Oct 26;60(11):1756. doi: 10.3390/medicina60111756.
3
Possible mechanisms of SARS-CoV-2-associated myocardial fibrosis: reflections in the post-pandemic era.
新型冠状病毒2型相关心肌纤维化的可能机制：大流行后时代的思考
Front Microbiol. 2024 Oct 8;15:1470953. doi: 10.3389/fmicb.2024.1470953. eCollection 2024.
4
Biomarkers in the evaluation of cardiac involvement in systemic sclerosis.生物标志物在系统性硬化症心脏受累评估中的应用
Rheumatol Immunol Res. 2024 Jul 15;5(2):99-106. doi: 10.1515/rir-2024-0013. eCollection 2024 Jun.
5
Therapeutic strategies for primary heart involvement in systemic sclerosis.系统性硬化症原发性心脏受累的治疗策略。
Rheumatol Immunol Res. 2024 Jul 15;5(2):72-82. doi: 10.1515/rir-2024-0010. eCollection 2024 Jun.
6
Speckle-tracking global longitudinal strain predicts death and cardiovascular events in patients with systemic sclerosis.斑点追踪整体纵向应变可预测系统性硬化症患者的死亡和心血管事件。
Eur Heart J Open. 2024 Apr 3;4(2):oeae023. doi: 10.1093/ehjopen/oeae023. eCollection 2024 Mar.
7
Cardiac involvement assessment in systemic sclerosis using speckle tracking echocardiography: a systematic review and meta-analysis.应用斑点追踪超声心动图评估系统性硬化症患者的心脏受累情况：系统评价和荟萃分析。
BMJ Open. 2023 Feb 16;13(2):e063364. doi: 10.1136/bmjopen-2022-063364.
8
Primary heart involvement in systemic sclerosis, from conventional to innovative targeted therapeutic strategies.系统性硬化症中心脏的原发性受累：从传统治疗策略到创新的靶向治疗策略
J Scleroderma Relat Disord. 2022 Oct;7(3):179-188. doi: 10.1177/23971983221083772. Epub 2022 Mar 24.
9
Targeting Systemic Sclerosis from Pathogenic Mechanisms to Clinical Manifestations: Why IL-6?从发病机制到临床表现靶向系统性硬化症：为何是白细胞介素-6？
Biomedicines. 2022 Jan 29;10(2):318. doi: 10.3390/biomedicines10020318.